Month: March 2022

In February 2022 AS Tallink Grupp transported 235 214 passengers, which is an 217.3% increase compared to February 2021. The number of cargo units increased by 24.8% to 32 958 units and the number of passenger vehicles increased by 143.0% to 45 295 units in the same comparison. AS Tallink Grupp passenger, cargo unit and passenger vehicles numbers for February 2022 were the following:  February 2022 February 2021 ChangePassengers 235 214 74 129 217.3%Finland – Sweden 79 233 18 223 334.8%Estonia – Finland 139 708 52 748 164.9%Estonia – Sweden 16 273 3 158 415.3%Latvia – Sweden 0 0 0.0%       Cargo Units 32 958 26 407 24.8%Finland – Sweden 5 834 5 318 9.7%Estonia – Finland 22 937 17 600 30.3%Estonia – Sweden 4 187 3 489 20.0%Latvia – Sweden 0 0 0.0%       Passenger Vehicles 45 295 18 642 143.0%Finland...

The Lithuanian subsidiary of Harju Elekter Group, Harju Elekter UAB, signed a contract on 1 March 2022 with U.S. Steel Corporation (Exploratory Ventures LLC) to produce low voltage drives and MCC systems to control 1500 motors that will be used in new Big River Steel facility in Arkansas. The beginning of production and supplies are scheduled for this year. Production and deliveries will take place until April 2023. The approximate volume of the contract is 10 million euros. Founded in 1901, United States Steel Corporation is a leading steel producer that serves the automotive, construction, appliance, energy, containers, and packaging industries with high value-added steel products such as U. S. Steel’s proprietary XG3™ advanced high-strength steel. The company also maintains iron ore production and has an annual raw steelmaking capability...

ANNOUNCEMENT NO. 55 – 3 MARCH 2022 3 March 2022 Below please find the complete proposals for the annual general meeting in Dampskibsselskabet NORDEN A/Sat 2.00 p.m. CET on Thursday 24 March 2022 see notice of 18 February 2022. The following proposals have been made: Re. item C on the agenda: Proposed appropriation of profits or cover of loss in accordance with the adopted annual report.                        The Board of Directors proposes that profits be distributed as follows:DKK 18.00 in dividend per share of DKK 1 totalling DKK 705.6 million mUSD 107.1Reserve for net revaluation according to the equity method mUSD -117.8Retained earnings mUSD 215.2Total profits mUSD 204.5Re. item D on the agenda: Election of members to the Board of Directors         The Board of Directors proposes re-election of:         Klaus...

ANNOUNCEMENT NO. 54 – 3 MARCH 2022 NORDEN’s annual report 2021 is attached as a zip file, in accordance with ESEF regulation. In addition, a PDF version of the annual report as well as a summary of the Q4 and full-year 2021 results are attached. Annual Report 2021 and Outlook 2022Today, the Board of Directors approved the annual report for 2021 with selected highlights below: Full-year resultsProfit for the year: USD 205 million (2020: USD 86 million) Return on equity: Increased to 22% (2020: 10%) Adjusted Result: USD 198 million (2020: USD 106 million)Returning capital to shareholdersProposed dividend of DKK 18 per share Initiating new share buyback programme of up to USD 30 millionOutlook 2022 Based on good positioning and active trading in a continued strong and volatile dry cargo market, NORDEN expects profit for the...

Bagsværd, Denmark, 3 March 2022 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The Strategic Aspirations 2025 were introduced in 2019 to reflect the broad aspects of Novo Nordisk’s business including purpose and sustainability (ESG), the sustained growth opportunities until 2025 across therapy areas and geographies as well as future growth drivers of Novo Nordisk in the research and development pipeline. The day will be centred around the Strategic Aspirations and during the day, senior management presentations will cover corporate strategy and research and early development strategy, Environmental, Social and Governance (ESG) strategies and performance as well as commercial strategies, research and development pipeline and performance within...

Press Release, 3 March 2022 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q3 for the financial year 2021/22 will be published at 08:00 CET on March 10, 2022. A telephone conference will be held at 09:00 CET on March 10, 2022. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call +46 8 566 426 51 and enter code 25519102# minutes before start. The presentation will be published on group.systemair.com For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com Systemair in briefSystemair is a leading ventilation company with operations in 54 countries in Europe, North America, South America, the Middle East, Asia, Australia...

VYVGART® (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial launch underwayTopline results from Phase 3 bridging study of subcutaneous (SC) efgartigimod in generalized myasthenia gravis (gMG) on track for first quarter 2022Malini Moorthy appointed as General CounselManagement to host conference call today at 2:30 pm CET (8:30 am ET)March 3, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2021 and provided a fourth quarter business update. “2021 was a transformational year for argenx, culminating with the FDA approval of VYVGART, our first-in-class FcRn blocker, in...